HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sidhu, J. S. Articles by Kaski, J.-C. Search for Related Content PubMed PubMed Citation Articles by Sidhu, J. S. Articles by Kaski, J.-C.

The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients

^* Coronary Artery Disease Research Unit, Cardiological Sciences, St. George's Hospital Medical School, London, United Kingdom.

View larger version (14K): [in a new window]   Figure 1 Effect of rosiglitazone on E-selectin and von Willebrand factor levels. Paired results at baseline and after 12 weeks of treatment are shown in each treatment group. Boxes indicate mean values, and bars represent 95% confidence intervals. *p < 0.05 for the change in the rosiglitazone versus placebo group.

View larger version (13K): [in a new window]   Figure 2 Effect of rosiglitazone on fibrinogen and log (CRP) levels. Paired results at baseline and after 12 weeks of treatment are shown in each treatment group. Boxes indicate mean values, and bars represent 95% confidence intervals. p < 0.005 for the change in the rosiglitazone versus placebo group.